After the company reported strong second-quarter results, shares of NuVasive (NASDAQ:NUVA), a medical device company focused on minimally invasive spine surgery, jumped as much as 10% in early-morning trading on Wednesday. Shares were up about 9% as of 12:47 p.m. EDT.
Here are the key takeaways from the second quarter:
- Revenue jumped 3.7% to $292.1 million. That matched the consensus estimate on Wall Street.
- Gross margin expanded 60 basis points to 73.4%.
- GAAP net income was $15.0 million, or $0.29.
- Non-GAAP, or adjusted, net income was $32.8 million, or $0.63 per share. That figure was up about 9% when compared to the year-ago period and was ahead of the $0.56 that market-watchers were expecting.
The upbeat quarterly results allowed management to favorably tweak its full-year guidance:
|Metric||Previous Guidance Range||Updated Guidance Range|
|Revenue||$1.14 billion to $1.16 billion||Unchanged|
|Non-GAAP operating margin||15% to 15.5%||15.3% to 15.7%|
|Non-GAAP EPS||$2.20 to $2.30||$2.25 to $2.35|
For context, Wall Street is currently projecting $1.15 billion in full-year revenue and $2.29 in non-GAAP earnings per share (EPS).
Traders cheered the upbeat quarterly results and guidance boost.
NuVasive isn't the fastest-growing medical device company out there, but its quarterly results show that it is having success with steadily growing its top line and controlling costs, both of which are contributing to decent growth on the bottom line. With management calling for more "Steady Eddie" growth from here, investors have every reason to remain bullish on this dependable business.